Analysts Anticipate Guardant Health Inc (GH) Will Post Earnings of -$0.36 Per Share

Wall Street analysts predict that Guardant Health Inc (NASDAQ:GH) will report ($0.36) earnings per share for the current quarter, Zacks reports. Three analysts have provided estimates for Guardant Health’s earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.40). The firm is scheduled to announce its next quarterly earnings results on Monday, February 18th.

On average, analysts expect that Guardant Health will report full year earnings of ($1.12) per share for the current year, with EPS estimates ranging from ($1.16) to ($1.10). For the next financial year, analysts forecast that the business will report earnings of ($1.26) per share, with EPS estimates ranging from ($1.30) to ($1.24). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Guardant Health.

Guardant Health (NASDAQ:GH) last released its quarterly earnings results on Monday, November 19th. The company reported ($1.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($1.65). The firm had revenue of $21.70 million for the quarter, compared to analyst estimates of $17.44 million. The company’s revenue was up 95.5% compared to the same quarter last year.

Several equities analysts recently commented on GH shares. JPMorgan Chase & Co. started coverage on shares of Guardant Health in a research report on Monday, October 29th. They issued an “overweight” rating and a $42.00 price objective for the company. Bank of America started coverage on shares of Guardant Health in a research report on Monday, October 29th. They issued a “neutral” rating and a $37.00 price objective for the company. Cowen started coverage on shares of Guardant Health in a research report on Monday, October 29th. They issued an “outperform” rating for the company. William Blair started coverage on shares of Guardant Health in a research report on Monday, October 29th. They issued an “outperform” rating for the company. Finally, Leerink Swann reaffirmed an “outperform” rating on shares of Guardant Health in a research report on Monday, October 29th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $39.50.

Shares of NASDAQ:GH traded up $1.24 during trading on Friday, reaching $38.40. The stock had a trading volume of 393,151 shares, compared to its average volume of 368,008. Guardant Health has a one year low of $27.04 and a one year high of $44.25.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides non-invasive cancer diagnostics. It offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes from circulating tumor DNA (ctDNA); and GuardantOMNI, a broader panel measuring various genes from ctDNA.

Read More: Moving Average (MA)

Get a free copy of the Zacks research report on Guardant Health (GH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply